PuSH - Publikationsserver des Helmholtz Zentrums München

Export: TXT Text RIS Endnote (RIS) BIB BibTeX
Stemmer, K. ; Finan, B.* ; DiMarchi, R.D.* ; Tschöp, M.H. ; Müller, T.D.

Insights into incretin-based therapies for treatment of diabetic dyslipidemia.

Adv. Drug Deliv. Rev. 159, 34-53 (2020)
Postprint DOI
Open Access Green
Derangements in triglyceride and cholesterol metabolism (dyslipidemia) are major risk factors for the development of cardiovascular diseases in obese and type-2 diabetic (T2D) patients. An emerging class of glucagon-like peptide-1 (GLP-1) analogues and next generation peptide dual-agonists such as GLP-1/glucagon or GLP-1/GIP could provide effective therapeutic options for T2D patients. In addition to their role in glucose and energy homeostasis, GLP-1, GIP and glucagon serve as regulators of lipid metabolism. This review summarizes the current knowledge in GLP-1, glucagon and GIP effects on lipid and lipoprotein metabolism and frames the emerging therapeutic benefits of GLP-1 analogs and GLP-1-based multiagonists as add-on treatment options for diabetes associated dyslipidemia.
Impact Factor
Scopus SNIP
Web of Science
Times Cited
Scopus
Cited By
Altmetric
13.300
3.732
5
13
Tags
Anmerkungen
Besondere Publikation
Auf Hompepage verbergern

Zusatzinfos bearbeiten
Eigene Tags bearbeiten
Privat
Eigene Anmerkung bearbeiten
Privat
Auf Publikationslisten für
Homepage nicht anzeigen
Als besondere Publikation
markieren
Publikationstyp Artikel: Journalartikel
Dokumenttyp Review
Schlagwörter Diabetes ; Dyslipidemia ; Incretins ; Lipoproteins ; Obesity; Glucagon-like Peptide-1; Gastric-inhibitory Polypeptide; Dependent Insulinotropic Polypeptide; Lipoprotein-lipase Activity; Low-density-lipoprotein; Dipeptidyl Peptidase-4 Inhibitor; Impaired Glucose-tolerance; Brown Adipose-tissue; High-fat; Receptor Agonist
Sprache englisch
Veröffentlichungsjahr 2020
HGF-Berichtsjahr 2020
ISSN (print) / ISBN 0169-409X
e-ISSN 1872-8294
Zeitschrift Advanced Drug Delivery Reviews
Quellenangaben Band: 159, Heft: , Seiten: 34-53 Artikelnummer: , Supplement: ,
Verlag Elsevier
Verlagsort Amsterdam
Begutachtungsstatus Peer reviewed
Institut(e) Institute of Diabetes and Obesity (IDO)
POF Topic(s) 90000 - German Center for Diabetes Research
30201 - Metabolic Health
Forschungsfeld(er) Helmholtz Diabetes Center
PSP-Element(e) G-501900-221
G-502200-001
Förderungen German Center for Diabetes Research (DZD e.V.)
Helmholtz Alliance ICEMED
Helmholtz Initiative on Personalized Medicine iMed by Helmholtz Association
Helmholtz cross-program topic "Metabolic Dysfunction"
German Research Foundation Grants
European Research Council ERC AdG HypoFlam
Alexander von Humboldt Foundation
DOI 10.1016/j.addr.2020.05.008
WOS ID WOS:000600557400004
Scopus ID 85086358886
Erfassungsdatum 2020-06-23
[➜Korrektur melden]